Ernest Choy
Institute of Infection and Immunity, Cardiff University School of Medicine · Academic Dept of Rheumatology Kings College London
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ernest Choy as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03241108 · Study of an Anti-TLR4 mAb in Rheumatoid ArthritisLight Chain Bioscience - Novimmune SA · completed · Rheumatoid Arthritis · principal investigator
- Ph2NCT01323374 · Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With FibromyalgiaChelsea Therapeutics · completed · Fibromyalgia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:34 UTC. The ranking covers the 200 most relevant of 90 PubMed records, and a shared surname and initials can bring in a namesake. All 90 on PubMed
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.Arthritis Rheum · 2005730 citationsRCR 20.2
- 591 citationsRCR 21.6
- 461 citationsRCR 16.3
- 407 citationsRCR 8.8
- 279 citationsRCR 29.8
- 271 citationsRCR 17.7
- Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.Arthritis Rheum · 2007216 citationsRCR 6.7
- The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.Br J Rheumatol · 1995215 citationsRCR 5.8
- Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.J Clin Oncol · 2012205 citationsRCR 4.9
- Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.Lancet Oncol · 2019188 citationsRCR 8.9